Palisade Bio (PALI)
NASDAQ:PALI

Palisade Bio (PALI) Stock Price & Analysis

387 Followers

PALI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.74 - $76.50
Previous Close$2.73
Volume599.88K
Average Volume (3M)3.73M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$13.98M
Total Debt (Recent Filing)$692.00K
Price to Earnings (P/E)-0.1
Beta0.73
Next EarningsMar 17, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-19.06
Shares Outstanding3,965,188
R-Squared0.09
Standard Deviation0.25
10 Day Avg. Volume1,424,498
30 Day Avg. Volume3,731,474
Price to Book (P/B)0.93
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusHold
Alpha-0.10
Number of Analyst Covering1


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

PALI FAQ

What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $1.74 and its highest was $76.50 in the past 12 months.
    What is Palisade Bio’s market cap?
    Currently, no data Available
    When is Palisade Bio’s upcoming earnings report date?
    Palisade Bio’s upcoming earnings report date is Mar 17, 2023 which is in 38 days.
      How were Palisade Bio’s earnings last quarter?
      Palisade Bio released its earnings results on Nov 14, 2022. The company reported -$4 earnings per share for the quarter, the consensus estimate of -$4 by $0.
        Is Palisade Bio overvalued?
        According to Wall Street analysts Palisade Bio’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Palisade Bio pay dividends?
          Palisade Bio does not currently pay dividends.
          What is Palisade Bio’s EPS estimate?
          Palisade Bio’s EPS estimate is -$2.44.
            How many shares outstanding does Palisade Bio have?
            Palisade Bio has 3,965,188 shares outstanding.
              What happened to Palisade Bio’s price movement after its last earnings report?
              Palisade Bio reported an EPS of -$4 in its last earnings report, expectations of -$4. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Palisade Bio?
                Currently, no hedge funds are holding shares in PALI

                ---

                Palisade Bio Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -94.81%
                12-Months-Change

                Fundamentals

                Return on Equity
                -115.80%
                Trailing 12-Months
                Asset Growth
                -0.05%
                Trailing 12-Months
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Palisade Bio

                Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Avenue Therapeutics
                One World Pharma
                Otonomy
                Ampio Pharmaceuticals
                Earth Science Tech

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis